Related Experiment Video

Updated: Mar 12, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma

Alejo Rodriguez-Vida1, Michiel Strijbos2, Thomas Hutson3

  • 1Department of Medical Oncology , IMIM Hospital del Mar Medical Research Institute , Barcelona , Spain.

ESMO Open
|November 16, 2016
PubMed

Insights

New treatments for metastatic renal cell carcinoma (RCC) include targeted therapies and immunotherapies. Identifying biomarkers is crucial for selecting patients who will benefit most from these advanced treatments.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Metastatic renal cell carcinoma (RCC) treatment has evolved from cytokines to targeted therapies.
  • Novel immunotherapies targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) pathways show promise for RCC management.

Approach:

  • This review examines evidence on biomarkers for targeted agents and immunotherapies in metastatic RCC.
  • Focus is on prognostic and predictive biomarkers to guide patient selection.

Key Points:

  • Targeted therapies and immunotherapies have improved outcomes in metastatic RCC.
  • Patient selection based on biomarkers is essential for treatment success.
  • Biomarker research is key to personalizing metastatic RCC treatment.

Conclusions:

  • Effective patient stratification is critical for optimizing outcomes with novel metastatic RCC therapies.
  • Further research into prognostic and predictive biomarkers will enhance the efficacy of signal transduction and immunotherapy agents.
Keywords:
BiomarkerImmunotherapyProgrammed cell death-1Renal cell carcinomaTyrosine kinase inhibitor

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K